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DObjective: With improving operative mortality for staged palliation of hypoplastic left heart syndrome, inter-
stage death accounts for an increasing proportion of hypoplastic left heart syndrome mortality. We investigated
risk factors for death or cardiac transplantation during the interstage period between bidirectional Glenn and
Fontan procedures in children with hypoplastic left heart syndrome.
Methods: Patients with hypoplastic left heart syndrome who underwent bidirectional Glenn between August
1995 and June 2007 were screened. Standard risk patients, defined by having been discharged after both
Norwood and bidirectional Glenn, were included for analysis. Patient demographic, echocardiographic, cardiac
catheterization, and operative data were reviewed. Interstage attrition was defined as death or cardiac transplan-
tation more than 30 days after bidirectional Glenn and before the Fontan procedure. Statistical analysis was
carried out using the Student t test, Pearson chi-square correlation, and Cox proportional hazard modeling for
multivariable analysis.
Results: Ninety-two patients with hypoplastic left heart syndrome were alive at 30 days after bidirectional
Glenn. Of these patients, 8 died and 3 underwent cardiac transplantation at a median of 391 days (range, 59–
1175 days) after bidirectional Glenn, yielding an interstage attrition rate of 12%. Removing the 7 patients
who are still awaiting Fontan (but all of whom are at least 3.5 years after bidirectional Glenn) adjusts the attrition
rate to 13%. Interstage attrition did not correlate with hemodynamic data obtained at cardiac catheterization,
aortic arch obstruction, or right ventricular dysfunction. Multivariable analysis demonstrated that the presence
of moderate or severe tricuspid valve regurgitation (hazard ratio, 6.02; 95% confidence interval, 1.56–23.24;
P<.01) and weight z score (hazard ratio, 0.38; 95% confidence interval, 0.16–0.88; P¼ .02) were independent
preoperative risk factors for interstage attrition.
Conclusions: Interstage attrition between bidirectional Glenn and Fontan procedures occurred in 12% of our
study population. Moderate or greater tricuspid valve regurgitation and low weight z score at the time of
bidirectional Glenn are important risk factors for interstage attrition between the bidirectional Glenn and Fontan
procedures in children with hypoplastic left heart syndrome. (J Thorac Cardiovasc Surg 2011;142:511-6)Hypoplastic left heart syndrome (HLHS) accounts for more
infant mortality than any other congenital heart disease in
the United States. Furthermore, 5-year survival for HLHS
ranges from 50% to 70% in multiple prior reports.1-7
With improving operative mortality for staged palliation
of HLHS, interstage death accounts for an increasing pro-
portion of the mortality.8 The incidence of interstage death
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The Journal of Thoracic and Castage II) palliation has been reported at 9% to 16%, and risk
factors for death during this period have been extensively
investigated.1,2,6,9-12
The incidence of interstage attrition between BDG and
Fontan (stage III palliation) ranges from 6% to 9% in stud-
ies with significant incomplete follow-up rates.6,9,13 Also,
the risk factors for interstage attrition in this group have
not been well delineated in the current era. The purpose
of this study is to investigate risk factors for interstage attri-
tion as defined by death or cardiac transplantation during
the interstage period between BDG and Fontan palliation
in children with HLHS.MATERIALS AND METHODS
Patients with a diagnosis of HLHSwho underwent Norwood stage I pal-
liation at Texas Children’s Hospital between August 1995 and June 2007
were screened. Other single ventricle anatomic variants were excluded, in-
cluding right ventricular-dominant atrioventricular canal, Shone’s syn-
drome, heterotaxy syndrome, double-outlet right ventricle, and isolated
mitral or aortic atresia with a ventricular septal defect. Seven patients had
a hospital length of stay of more than 2.5 months after the stage I palliation,rdiovascular Surgery c Volume 142, Number 3 511
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D5 of whom did not leave the hospital. When compared with the rest of the
group, these 7 patients were outliers and expected to have a difficult postop-
erative course after BDG. They were excluded from further analysis. In
addition, patients who died within 30 days of BDG were excluded.
A total of 92 patients were included in the initial cohort, all of whom
were discharged after both their stage I and BDG palliations. These patients
were deemed to comprise a standard risk group, which could provide the
most pertinent insight into why unexpected attrition occurs after BDG.
As of November 2010, these patients had undergone Fontan palliation or
attrition (death or transplant) or were awaiting Fontan palliation
(Figure 1). Seven patients are awaiting Fontan palliation and were removed
from the risk factor analysis.
Analyzed data included patient demographics, cardiac anatomy, pre-
BDG echocardiograms, pre-BDG cardiac catheterization, intraoperative var-
iables, and postoperative hospital course. Routine use of antegrade cerebral
perfusion for stage 1 palliation was initiated in May 2000, and this variable
was included in the analysis as a surrogate for era. Traditional risk factors for
interstage mortality between stage 1 and 2 palliation were included in the
analysis. The primary outcome of interest was interstage attrition as defined
by death or cardiac transplantation occurring after hospital discharge after
BDGand before Fontan. The institutional review board of theBaylor College
of Medicine approved this retrospective review of patient medical records.
All patients had a pre-BDG echocardiogram read by a pediatric cardiol-
ogist with expertise in imaging. The last pre-BDG echocardiogram report
was included for analysis. Qualitative assessments of tricuspid and neo-
aortic valve regurgitation and of ventricular function were reported as
none, trivial, mild, moderate, or severe. This analysis was repeated for
all patients post-BDG echocardiograms performed before discharge.
All patients but 1 underwent pre-BDG cardiac catheterization at our insti-
tution.Hemodynamicdatawere retrospectively collected fromcatheterization
reports. These data included saturations, pressures, calculated pulmonary vas-
cular resistance, and Qp:Qs. Catheter-based interventions were recorded,
including atrial septoplasty, aortic arch angioplasty, and aortic arch stenting.
All patients hadoperative reports available for analysis.Additional surgical
interventions at the time of the BDG, including atrial septectomy, aortic arch
repair, tricuspid valvuloplasty, and pulmonary artery repair, were recorded.
Data regarding postoperative hospital course after BDG were collected
from the medical record. These data include length of intubation, hospital
length of stay, and presence of a pleural effusion significant enough to require
drainage by a new chest tube after removal of the initial operative chest tube.
Statistical analysis was performed using SPSS version 16.0 (SPSS Inc,
Chicago, Ill). Univariate analysis was performed for demographic, pre-
BDG echocardiogram, pre-BDG catheterization, and perioperative vari-
ables. Two-tailed Student t test was used for continuous variables. Pearson
chi-square or Fisher exact test was used for categoric variables. Survival
graphs were constructed using Kaplan–Meier test. A population growth
curve was constructed by taking patient weights at multiple times before
BDG. Cox regression analysis was used to identify independent predictors
of attrition. We performed a multivariable analysis by including variables
in the Cox regression model that produced a significance value of less
than 0.10 on univariate analysis.RESULTS
The study cohort consisted of 92 patients (Figure 1).
There were 8 deaths and 3 transplants before Fontan,512 The Journal of Thoracic and Cardiovascular Surgyielding an interstage attrition rate of 12%. Excluding the
7 patients awaiting Fontan increased the interstage attrition
rate to 13%. Interstage attrition occurred at a median of 391
days (range, 59–1175 days) after BDG. Seventy-three pa-
tients have undergone Fontan at a mean time of 3.4 years af-
ter BDG (range, 1.6–5.8 years). The family of 1 patient
declined Fontan palliation because of significant neurologic
injury. This patient underwent BDG approximately 8 years
ago and is included in the risk factor analysis.
Patients who died during the interstage period are listed
in Table 1, along with clinical characteristics and suspected
causes of death. Six patients died with right ventricular dys-
function. Two patients died unexpectedly at home. One pa-
tient died of native aortic valve regurgitation leading to left
ventricular dilation and right ventricular dysfunction. Three
patients underwent cardiac transplantation for right ventric-
ular dysfunction during the interstage period. The trans-
plants occurred 245, 288, and 540 days after BDG. Two
patients who died had cardiac anomalies beyond those nor-
mally associated with HLHS. One patient had a dysplastic
native pulmonary valve, and one patient was born with a hy-
poplastic right lung and left pulmonary vein stenosis subse-
quently developed.
Analysis of demographic variables (Table 2) revealed no
association between interstage attrition and the following
variables: gender, anatomic subtype, use of antegrade cere-
bral perfusion, restrictive atrial septum at birth, age or
weight at stage 1 palliation (surrogate for delayed presenta-
tion), stage 1 palliation operative characteristics, or age at
BDG. Four patients had genetic syndromes, including
Noonan syndrome, chromosome 6 and 17 translocation
with minimal clinical sequelae, and 2 undiagnosed genetic
syndromes. One of the patients with an undiagnosed genetic
syndrome underwent heart transplantation 245 days after
BDG. The small number of genetic conditions precluded
further statistical analysis. All patients underwent stage 1
palliation with a systemic to pulmonary artery shunt; there-
fore, we could not analyze any differences between these
shunts and right ventricle to pulmonary artery conduits.
Only 3 patients were born prematurely. No patient required
extracorporeal membrane oxygen after stage 1 palliation.
Themedian length of stay after stage 1 palliation was longer
for the patients who had interstage attrition (32 days; range,
17–66) than for thosewho did not (21 days; 9–62) (P¼ .03).
Weight at the time of BDG, whether expressed as an abso-
lute number or as a z score, was associated with interstage
attrition (Table 2). Figure 2 demonstrates a tapering of the
growth curve before BDG in the interstage attrition group.
No patient required unplanned surgical intervention be-
tween stage 1 palliation and BDG.
Analysis of pre-BDG echocardiographic data (Table 3)
revealed no association between right ventricular dysfunc-
tion or neoaortic regurgitation and interstage attrition. Mod-
erate or severe tricuspid valve regurgitation was present onery c September 2011
HLHS s/p BDG
N=101
Excluded
N=9
Cohort
N=92
Death within 30 
days of BDG
N=2
Death
N=8
Transplant
N=3
Fontan
N=74
Awaiting
Fontan
N=7
Prolonged LOS
After S1P
N=7
Death
N=4
Fontan
N=3
FIGURE 1. Outcomes of 101 patients who underwent BDG. BDG, Bidirectional Glenn; HLHS, hypoplastic left heart syndrome; LOS, length of stay; S1P,
stage 1 palliation.
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Dthe pre-BDG echocardiogram in a significantly greater pro-
portion of patients who did have interstage attrition (55%)
than in those who did not (14%) (P<.01). A Kaplan–Meier
survival curve (Figure 3) was constructed for patients di-
chotomized by the presence of moderate or severe tricuspid
valve regurgitation before BDG.
Analysis of pre-BDG catheterization data (Table 3) re-
vealed no statistically significant associations betweenTABLE 1. List of patients who experienced death or cardiac transplantati
Patient Anatomy Comorbidities
Hospital
LOS after
Norwood (d)
Pre-BDG
RV function
1 AA, MS None 31 Normal
2 AS, MA Hypoplastic
right lung
25 Normal
3 AA, MS Dysplastic
pulmonary valve
22 Normal
4 AA, MA None 65 Normal
5 AA, MA None 49 Depressed secondary
to recurrent coarctati
6 AA, MA None 35 Moderately depressed
7 AA, MA None 36 Normal
8 AS, MS None 29 Normal
9 AS, MS None 27 Normal
10 AA, MA None 21 Normal
11 AS, MS None 34 Normal
Comorbidities, causes of death or transplant, and time to death or transplant after BDG are
atresia; AS, aortic stenosis; MA, mitral atresia; MS, mitral stenosis.
The Journal of Thoracic and Caany hemodynamic variables and interstage attrition. In ad-
dition, there was no association between any catheterization
intervention and interstage attrition. Overall, the rate of
transcatheter interventions was not different between
groups.
Analysis of intraoperative procedures at BDG (Table 3)
revealed that tricuspid valvuloplasty occurred more com-
monly in patients who had attrition (27%) than in thoseon between bidirectional Glenn and Fontan
Pre-BDG
tricuspid
regurgitation
Death or
transplant
Months
after BDG
Cause of death or
transplant
Moderate Death 1.9 RV dysfunction
Trivial Death 4.4 Pulmonary vein stenosis
Moderate Death 9.3 Neoaortic regurgitation,
RV dysfunction
Moderate Death 12.8 Sudden death
on
Severe Death 13.6 RV dysfunction
Moderate Death 22.7 RV dysfunction, influenza A
Trivial Death 29.0 RV dysfunction
Mild Death 38.5 Sudden death
Mild Transplant 8.0 RV dysfunction after cardiac
arrest after BDG
Moderate Transplant 9.4 RV dysfunction, tricuspid
regurgitation
Trivial Transplant 17.7 LV dilation, RV dysfunction,
neoaortic regurgitation
delineated. LOS, Length of stay; LV, left ventricular; RV, right ventricular; AA, aortic
rdiovascular Surgery c Volume 142, Number 3 513
TABLE 2. Demographic variables of patients undergoing bidirectional
Glenn
Variable
Attrition
(n ¼ 11)
Alive
(n ¼ 74)
P
value
Anatomic subtype .5
AA/MA 73% (8/11) 57% (42/74)
AA/MS 0% (0/11) 11% (8/74)
AS/MA 0% (0/11) 7% (5/74)
AS/MS 27% (3/11) 26% (19/74)
Male gender 64% (7/11) 65% (48/74) .94
Restrictive atrial septum
at birth
9% (1/11) 19% (13/74) .48
Age at S1P (d) 5.9  2.5 7  4.7 .45
Weight at S1P (kg) 2.9  0.5 3.1  0.5 .19
Pre-ACP S1P 18% (2/11) 36% (27/74) .23
S1P CPB time (min) 181  40 186  49 .8
S1P crossclamp time (min) 84  22 77  22 .36
S1P DHCA time (min) 27  17 27  20 .92
(ACP era, min) 23  10 (n ¼ 9) 17  11 (n ¼ 47) .15
Median hospital length
of stay after S1P (d)
32 (17,66) 21 (9,62) .03
Age at BDG (d) 178  55 202  66 .26
Weight at BDG (kg) 5.32  0.79 6.16  1.02 .01
Weight at BDG (z score) 2.26  0.68 1.74  0.79 .04
Values expressed asmean standard deviation, or median (range). AA,Aortic atresia;
AS, aortic stenosis; MA, mitral atresia; MS, mitral stenosis; S1P, stage 1 palliation;
CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest time;
ACP, antegrade cerebral perfusion.
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FIGURE 2. Growth curve before BDG. BDG, Bidirectional Glenn;
HLHS, hypoplastic left heart syndrome.
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Dwho did not (5%), although this difference did not achieve
statistical significance (P ¼ .06). Undergoing atrial septec-
tomy, aortic arch repair, or pulmonary artery repair was not
associated with interstage attrition.
Analysis of the postoperative hospital course data re-
vealed that patients who had interstage attrition had longer
intubation times (median 2 days vs 1 day, P<.01) and hos-
pital length of stay (median 19 days vs 6 days, P<.01) after
BDG than patients who did not. There was no statistically
significant difference in postoperative pleural effusions be-
tween the groups (18% vs 6%, P ¼ .2).
We performed a multivariable analysis (Table 4) by in-
cluding variables in the Cox regression model that produced
a significance value of less than .10 on univariate analysis.
The variables included in the analysis were post-stage I pal-
liation hospital length of stay, weight z score at BDG palli-
ation, moderate or severe tricuspid valve regurgitation, and
tricuspid valve repair. Multivariable analysis demonstrated
that the presence of moderate or severe tricuspid valve re-
gurgitation (hazard ratio, 6.02; 95% confidence interval,
1.56–23.24; P < .01) and weight z score (hazard ratio,
0.38; 95% confidence interval, 0.16–0.88; P¼ .02) were in-
dependent preoperative risk factors for interstage attrition.
We also investigated whether tricuspid valve repair in pa-
tients with moderate or severe tricuspid valve regurgitation
was inversely associated with interstage attrition. There
were 17 patients (18%) with moderate or severe tricuspid514 The Journal of Thoracic and Cardiovascular Surgvalve regurgitation. Seven patients underwent valve repair
with echocardiographic improvement of the regurgitation
to mild or less noted. Of the 7 patients who underwent valve
repair, 4 died. Of the 10 patients who did not undergo valve
repair, 3 died. There was no difference in interstage attrition
between these groups (P¼ .26). Finally, 7 other patients had
moderate or severe tricuspid valve regurgitation on echocar-
diography performed after BDG. Three of these patients
had interstage attrition. Moderate or severe tricuspid valve
regurgitation on echocardiography performed after BDG
occurred more frequently in the attrition group, although
this difference did not meet statistical significance (27%
vs 5%, P ¼ .06) (Table 3).DISCUSSION
The objective of this study was to investigate risk factors
for interstage attrition between BDG and Fontan palliation
in children with HLHS. Our results demonstrate that mod-
erate or severe tricuspid valve regurgitation and low weight
z score at the time of BDG are important risk factors for sub-
sequent interstage attrition. Although right ventricular dys-
function was not associated with interstage attrition in our
analysis, significant tricuspid valve regurgitation may result
from and contribute to volume overload, which may have
long-lasting effects on ventricular function. Traditional
risk factors for interstage mortality between stage 1 and 2
palliation (genetic syndromes, prematurity, restrictive atrial
septum at birth, age at stage 1 palliation, and need for extra-
corporeal membrane oxygen around stage 1 palliation)
were not found to be risk factors for attrition after BDG
or could not be evaluated because of insufficient numbers.
The strengths of this study are in the large number of pa-
tients, exclusion of HLHS variants, and thorough analysis
of risk factors at the time of BDG palliation.
Previous studies have produced conflicting results in re-
gard to whether atrioventricular valve regurgitation is
a risk factor for poor outcome after BDG. Ashburn and col-
leagues6 reported that repair of tricuspid valve regurgitationery c September 2011
TABLE 3. Echocardiographic and catheterization data before bidirectional Glenn
Variable Attrition (n ¼ 11) Alive (n ¼ 74) P value
Echocardiographic (pre-BDG)
RV dysfunction (moderate or more) 9% (1/11) 12% (9/74) 1.0
Tricuspid regurgitation (moderate or more) 55% (6/11) 14% (10/74) <.01
Neoaortic valve regurgitation (more than mild) 0% (0/11) 2% (2/74) 1.0
Catheterization
Right ventricular end-diastolic pressure (mm Hg) 9.6  5.2 8.4  2.1 .24
Pulmonary artery pressure (mm Hg) 13.6  3.7 13.4  3.4 .87
Pulmonary vascular resistance (Wood units) 1.4  0.6 1.8  0.9 .12
Qp:Qs 1.5  0.5 1.3  0.6 .35
Arteriovenous O2 difference (%) 26  6 28  9 .37
Significant aortic arch obstruction 18% (2/11) 19% (14/74) 1.0
Atrial septal gradient 9% (1/11) 18% (13/74) 1.0
Aortic arch angioplasty 9% (1/11) 18% (13/74) 1.0
Transcatheter intervention 18% (2/11) 27% (20/74) .8
Intraoperative factors
Aortic arch repair 18% (2/11) 19% (14/74) 1.0
Tricuspid valve repair 27% (3/11) 5% (4/74) .06
Atrial septectomy 18% (2/11) 18% (13/74) 1.0
Pulmonary artery repair 27% (3/11) 26% (19/74) 1.0
Echocardiographic (post-BDG)
RV dysfunction (moderate or more) 27% (3/11) 11% (8/74) .3
Tricuspid regurgitation (moderate or more) 27% (3/11) 5% (4/74) .06
Neoaortic valve regurgitation (greater than mild) 9% (1/11) 2% (2/74) 1.0
Intraoperative factors at BDG and echocardiographic data after BDG. Qp, Pulmonary blood flow; Qs, systemic blood flow; RV, right ventricular.
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Dat the time of BDG in patients with HLHS increased the risk
of death after BDG. Likewise, in an analysis of risk factors
for all single ventricles undergoing BDG, Scheurer and col-
leagues14 found that moderate or severe atrioventricular
valve regurgitation predicted subsequent interstage attri-
tion. In contrast with these findings, Mahle and colleagues15
reported that atrioventricular valve regurgitation did not af-
fect survival in patients with a single ventricle undergoing
BDG. A possible explanation for these discrepant resultsFIGURE 3. Kaplan–Meier survival curve dichotomized by the presence
of moderate or severe tricuspid valve regurgitation before BDG. TR, Tri-
cuspid regurgitation.
The Journal of Thoracic and Cais that the volume load created by significant atrioventricu-
lar valve regurgitation is more deleterious to the systemic
right ventricle than to the systemic left ventricle. Previous
studies disagree on the benefit of routine valvuloplasty at
BDG in the setting of moderate or greater regurgitation.15,16
The number of patients undergoing valvuloplasty in our
study was insufficient to draw any conclusion with regard
to this controversy. Of note, we found a significant associa-
tion between moderate or greater atrioventricular valve re-
gurgitation on post-BDG echocardiography and interstage
attrition.
Lower weight at time of BDG was found to be a risk fac-
tor for interstage attrition in our analysis. The weight gain
demonstrated by the infants in our study corresponds well
to previous reports.17,18 We used weight z scores to adjust
for age at BDG. Anderson and colleagues19 demonstrated
that low weight z score at the time of BDG was associated
with longer postoperative hospital length of stay. PoorTABLE 4. Multivariable analysis of independent risk factors for
interstage attrition after bidirectional Glenn (n ¼ 85)
Variable HR 95% CI
P
value
Tricuspid valve regurgitation 6.02 1.56–23.24 <.01
Tricuspid valve repair 1.25 0.24–6.56 .79
Median hospital length of stay after S1P (d) 1.03 0.99–1.07 .21
Weight at BDG (z score) 0.38 0.16–0.88 .02
BDG (n ¼ 85). HR, Hazard ratio; CI, confidence interval; S1P, stage 1 palliation.
rdiovascular Surgery c Volume 142, Number 3 515
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Dweight gain may be a marker of poor nutritional support, the
degree of congestive heart failure, comorbidities, prolonged
hospitalization, or poor cardiac function. It is unclear
whether nutritional interventions, such as fortified feeds
or gastrostomy tube placement, could improve weight
gain before BDG or long-term outcomes. Our study also
confirms the findings of Ghanayem and colleagues18 dem-
onstrating diminished growth velocity at approximately 4
to 6 months of age for infants with HLHS and thus suggest-
ing that there may be no benefit of delaying the BDG pro-
cedure once a child attains a weight of 5 kg. Furthermore,
our findings raise the question of whether an early BDG
may be indicated in patients who are not gaining weight ap-
propriately. Individualizing the timing of BDG may be the
most appropriate strategy.
This study has several limitations. First, follow-up dura-
tion is limited, and a small number of patients (7/92, 8%)
were still awaiting Fontan palliation. Although we did ex-
clude these patients from the risk factor analysis, any further
death or transplant among this group of patients would in-
crease the overall rate of attrition. All of our attrition oc-
curred before 3 years post-BDG and all of our patients
awaiting Fontan are at least 3.5 years post-BDG, suggesting
that further attrition is unlikely. In prior studies, up to 40% of
patients were still awaiting Fontan palliation.6,9,13 Our more
complete follow-up may explain why our interstage attrition
rate (12%) seems higher than in prior studies (6%–
9%).6,9,13 Our attrition rate between BDG and 12 months
of age (3% [3/92] in our analyzed cohort, 6% [6/101] before
excluding patients) is similar to that reported by Ohye and
colleagues20 in a recent large multi-institutional trial
(6.3% [25/397]). Second, because of insufficient numbers,
certain traditional risk factors for interstage mortality be-
tween stage 1 palliation and BDG could not be effectively
analyzed. Third, potentially important variables, including
mode of feeding before BDG, right ventricular volumes
on echocardiography, and postoperative pulmonary artery
pressures after BDG, were unavailable for analysis. Finally,
our cohort spans more than 10 years ending in 2007;
therefore, attrition rates may not be representative of the
current era.
CONCLUSIONS
Survival after BDG for HLHS infants is high. Although
the causes of interstage attrition are varied, the majority
of deaths and transplantations result from progressive ven-
tricular dysfunction. Sudden unexpected death does occur
in this population. Moderate or greater tricuspid valve re-
gurgitation and low weight z score at BDG are important
risk factors for interstage attrition between the BDG and
Fontan palliations. With improving survival after stage 1
palliation and during the first interstage period, an increas-
ing number of candidates for BDG will likely be more mar-
ginal, with increased risk for subsequent interstage attrition.516 The Journal of Thoracic and Cardiovascular SurgImprovements in interstage outcomes after BDGmay result
from optimizing congestive heart failure therapies and nu-
tritional support before BDG, goals of home-monitoring
programs. Individualizing the timing of BDG palliation
and addressing significant tricuspid valve regurgitation
may also improve interstage outcomes after BDG.
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